Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vascular Biogenics stock | $2.35

Learn how to easily invest in Vascular Biogenics stock.

Vascular Biogenics Ltd is a biotechnology business based in the US. Vascular Biogenics shares (VBLT) are listed on the NASDAQ and all prices are listed in US Dollars. Vascular Biogenics employs 38 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vascular Biogenics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VBLT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vascular Biogenics stock price (NASDAQ: VBLT)

Use our graph to track the performance of VBLT stocks over time.

Vascular Biogenics shares at a glance

Information last updated 2021-10-25.
Latest market close$2.35
52-week range$1.09 - $3.17
50-day moving average $2.21
200-day moving average $2.20
Wall St. target price$5.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.51

Buy Vascular Biogenics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vascular Biogenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vascular Biogenics price performance over time

Historical closes compared with the close of $2.35 from 2021-10-22

1 week (2021-10-19) 6.33%
1 month (2021-09-24) 11.90%
3 months (2021-07-26) 5.38%
6 months (2021-04-26) 24.34%
1 year (2020-10-26) 102.59%
2 years (2019-10-25) 82.17%
3 years (2018-10-26) 78.03%
5 years (2016-10-26) 5

Vascular Biogenics financials

Revenue TTM $771,000
Gross profit TTM $528,000
Return on assets TTM -28.5%
Return on equity TTM -56.52%
Profit margin 0%
Book value $0.88
Market capitalisation $146.6 million

TTM: trailing 12 months

Shorting Vascular Biogenics shares

There are currently 2.2 million Vascular Biogenics shares held short by investors – that's known as Vascular Biogenics's "short interest". This figure is 8.8% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Vascular Biogenics shares can be evaluated.

Vascular Biogenics's "short interest ratio" (SIR)

Vascular Biogenics's "short interest ratio" (SIR) is the quantity of Vascular Biogenics shares currently shorted divided by the average quantity of Vascular Biogenics shares traded daily (recently around 294368.67305062). Vascular Biogenics's SIR currently stands at 7.31. In other words for every 100,000 Vascular Biogenics shares traded daily on the market, roughly 7310 shares are currently held short.

However Vascular Biogenics's short interest can also be evaluated against the total number of Vascular Biogenics shares, or, against the total number of tradable Vascular Biogenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vascular Biogenics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Vascular Biogenics shares in existence, roughly 30 shares are currently held short) or 0.0452% of the tradable shares (for every 100,000 tradable Vascular Biogenics shares, roughly 45 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vascular Biogenics.

Find out more about how you can short Vascular Biogenics stock.

Vascular Biogenics share dividends

We're not expecting Vascular Biogenics to pay a dividend over the next 12 months.

Vascular Biogenics share price volatility

Over the last 12 months, Vascular Biogenics's shares have ranged in value from as little as $1.09 up to $3.17. A popular way to gauge a stock's volatility is its "beta".

VBLT.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vascular Biogenics's is 1.0725. This would suggest that Vascular Biogenics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Vascular Biogenics overview

Vascular Biogenics Ltd. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications in Israel and the United States. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors.

Frequently asked questions

What percentage of Vascular Biogenics is owned by insiders or institutions?
Currently 18.68% of Vascular Biogenics shares are held by insiders and 19.225% by institutions.
How many people work for Vascular Biogenics?
Latest data suggests 38 work at Vascular Biogenics.
When does the fiscal year end for Vascular Biogenics?
Vascular Biogenics's fiscal year ends in December.
Where is Vascular Biogenics based?
Vascular Biogenics's address is: 8 HaSatat Street, Hevel Modi'in, Israel, 7178106
What is Vascular Biogenics's ISIN number?
Vascular Biogenics's international securities identification number is: IL0011327454
What is Vascular Biogenics's CUSIP number?
Vascular Biogenics's Committee on Uniform Securities Identification Procedures number is: M96883109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site